Uterine carcinomas in tetrabromobisphenol a-exposed wistar han rats harbor increased tp53 mutations and mimic high-grade type i endometrial carcinomas in women

Toxicologic Pathology

Volumn 43, Issue 8, 2015, Pages 1103-1113

  Harvey, Janice B ^a,b   Osborne, Tanasa S ^a   Hong, Hue Hua L ^a   Bhusari, Sachin ^a   Ton, Tai Vu ^a   Pandiri, Arun R ^c   Masinde, Tiwanda ^a   Dunnick, June ^d   Peddada, Shyamal ^d   Elmore, Susan ^a   Hoenerhoff, Mark J ^a,e  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c EXPERIMENTAL PATHOLOGY LABORATORIES INC   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Ccnd1; Cdh1; Ctnnb1; dometrial carcinoma; Her2; Kras; tetrabromobisphenol A; Tp53; Wistar Han rats

Indexed keywords

CCND1 PROTEIN; CTNNB1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; INTERFERON REGULATORY FACTOR 1; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH3; PROTEIN P16; PROTEIN P53; TETRABROMOBISPHENOL A; UNCLASSIFIED DRUG; UVOMORULIN; POLYBROMINATED BIPHENYL; TP53 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRADING; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; GENE MUTATION; HIGH GRADE TYPE I ENDOMETRIAL CARCINOMA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MICROSATELLITE INSTABILITY; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR SUPPRESSOR GENE; UTERUS CARCINOMA; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; ENDOMETRIUM TUMOR; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; UTERUS; UTERUS CANCER; WISTAR RAT;

ANIMALS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; POLYBROMINATED BIPHENYLS; RATS; RATS, WISTAR; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS; UTERUS;

EID: 84948655323     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623315599256     Document Type: Article

References (42)

1. Adamovic T., Hamta A., Roshani L., Lu X., Rohme D., Helou K., Klinga-Levan K., Levan G., (2008). Rearrangement and allelic imbalance on chromosome 5 leads to homozygous deletions in the CDKN2A/2B tumor suppressor gene region in rat endometrial cancer. Cancer Genet Cytogenet 184, 9-21.
2. American Cancer Society. (2013). Cancer Facts and Figures 2013. American Cancer Society, Atlanta, GA.
3. American Cancer Society. (2014). Cancer Facts and Figures 2014. American Cancer Society, Atlanta, GA. Accessed March 22, 2014. http://www.cancer.org/cancer/endometrialcancer/detailedguide/endometrial-uterine-cancer-key-statistics.
4. Bailer A. J., Portier C. J., (1988). Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples. Biometrics 44, 417-31.
5. Behboudi A., Levan G., Hedrich H. J., Klinga-Levan K., (2001). High-density marker loss of heterozygosity analysis of rat chromosome 10 in endometrial adenocarcinoma. Genes Chromosomes Cancer 32, 330-41.
6. Beral V., Bull D., Reeves G., (2005). Endometrial cancer and hormone-replacement therapy in the million women study. The Lancet 365, 1543-51.
7. Bian Y.-S., Osterheld M.-C., Bosman F. T., Benhattar J., Fontolliet C., (2001). p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Mod Pathol 14, 397-403.
8. Blagosklonny M. V., (2000). p53 from complexity to simplicity: Mutant p53 stabilization, gain-of-function, and dominant-negative effect. Faseb J 14, 1901-07.
9. Dixon D., Alison R., Bach U., Colman K., Foley G. L., Harleman J. H., Haworth R., Herbert R., Heuser A., Long G., Mirsky M., Regan K., van Esch E., Westwood F.R., Vidal J., Yoshida M., (2014). INHAND: Nonproliferative and proliferative lesions of the rat and mouse female reproductive tract. J Toxicol Pathol 27, 1S-107S.
10. Doll A., Abal M., Rigau M., Monge M., Gonzalez M., Demajo S., Colas E., Llaurado M., Alazzouzi H., Planaguma J., Lohmann M. A., Garcia J., Castellvi S., Ramon y Cajal J., Gil-Moreno A., Xercavins J., Alameda F., Reventos J., (2008). Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol 108, 221-29.
11. Emons G., Fleckenstein G., Hinney B., Huschmand A., Heyl W., (2000). Hormonal interactions in endometrial cancer. Endocr Relat Cancer 7, 227-42.
12. George B., Datar R. H., Wu L., Cai J., Patten N., Beil S. J., Groshen S., Stein J., Skinner D., Jones P. A., Cote R. J., (2007). p53 gene and protein status: The role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol 25, 5352-58.
13. Gosavi R. A., Knudsen G. A., Birnbaum L. S., Pedersen L. C., (2013). Mimicking of estradiol binding by flame retardants and their metabolites: A crystallographic analysis. Environ Health Perspect 121, 1194-99.
14. Hamers T., Kamstra J. H., Sonneveld E., Murk A. J., Kester M. H., Andersson P. L., Legler J., Brouwer A., (2006). In vitro profiling of the endocrine-disrupting potency of brominated flame retardants. Toxicol Sci 92, 157-73.
15. Horn L. C., Meinel A., Handzel R., Einenkel J., (2007). Histopathology of endometrial hyperplasia and endometrial carcinoma: An update. Ann Diagn Pathol 11, 297-311.
16. Kitamura S., Suzuki T., Sanoh S., Kohta R., Jinno N., Sugihara K., Yoshihara S., Fujimoto N., Watanabe H., Ohta S., (2005). Comparative study of the endocrine-disrupting activity of bisphenol A and 19 related compounds. Toxicol Sci 84, 249-59.
17. Kropveld A., van Mansfeld A. D. M., Nabben N., Hordijk G. J., Slootweg P. J., (1996). Discordance of p53 status in matched primary tumours and metastases in head and neck squamous cell carcinoma patients. Eur J Cancer B Oral Oncol 32, 388-393.
18. Kuroboshi H., Okubo T., Kitaya K., Nakayama T., Daikoku N., Fushiki S., Honjo H., (2003). Interferon regulatory factor-1 expression in human uterine endometrial carcinoma. Gynecol Oncol 91, 354-58.
19. Lax S. F., (2004). Molecular genetic pathways in various types of endometrial carcinoma: From a phenotypical to a molecular-based classification. Virchows Arch 444, 213-23.
20. Liu F. S., (2007). Molecular carcinogenesis of endometrial cancer. Taiwan J Obstet Gynecol 46, 26-32.
21. Llobet D., Pallares J., Yeramian A., Santacana M., Eritja N., Velasco A., Dolcet X., Matias-Guiu X., (2009). Molecular pathology of endometrial carcinoma: Practical aspects from the diagnostic and therapeutic viewpoints. J Clin Pathol 62, 777-85.
22. Matias-Guiu X., Catasus L., Bussaglia E., Lagarda H., Garcia A., Pons C., Munoz J., Arguelles R., Machin P., Prat J., (2001). Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 32, 569-77.
23. McConechy M. K., Ding J., Cheang M. C., Wiegand K. C., Senz J., Tone A. A., Yang W., Prentice L. M., Tse K., Zeng T., McDonald H., Schmidt A. P., Mutch D. G., McAlpine J. N., Hirst M., Shah S. P., Lee C. H., Goodfellow P. J., Gilks C. B., Huntsman D. G., (2012). Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol 228, 20-30.
24. Mills A. M., Longacre T. A., (2011). Atypical endometrial hyperplasia and well differentiated endometrioid adenocarcinoma of the uterine corpus. Surg Pathol 4, 149-98.
25. Mittal K. R., Barwick K. W., (1988). Diffusely infiltrating adenocarcinoma of the endometrium. A subtype with poor prognosis. Am J Surg Pathol 12, 754-58.
26. Modan B., Hartge P., Hirsh-Yechezkel G., Chetrit A., Lubin F., Beller U., Ben-Baruch G., Fishman A., Menczer J., Struewing J. P., Tucker M. A., Wacholder S., (2001). Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345, 235-40.
27. Nordlander C., Behboudi A., Levan G., Levan K. K., (2005). Allelic imbalance on chromosome 10 in rat endometrial adenocarcinomas. Cancer Genet Cytogenet 156, 158-66.
28. NTP (National Toxicology Program). (2013). Toxicology studies of tetrabromobisphenol A (CAS No. 79-94-7) in F344/NTac rats and B6C3F1/N mice and toxicology and carcinogenesis studies of tetrabromobisphenol A in Wistar Han [Crl:WI(Han)] rats and B6C3F1/N mice (gavage studies). NTP Technical Report Series. Accessed June 18, 2014. http://ntp.niehs.nih.gov/ntp/about-ntp/trpanel/2013/october/draft-tr-587.pdf.
29. NTP (National Toxicology Program). (2014a). Toxicology studies of antimony trioxide 10676-v (CASRN: 1309-64-4) in Wistar Han [Crl:WI(Han)] rats and B6C3F1/N mice and toxicology and carcinogenesis studies of antimony trioxide 10676-v in Wistar Han[Crl:WI(Han)] rats and B6C3F1/N mice (inhalation studies). NTP Technical Report Series. Accessed June 18, 2014. http://ntp.niehs.nih.gov/?objectid=BCD52E6A-123F-7908-7BD5298A5D912AF9.
30. NTP (National Toxicology Program). (2014b). Toxicology studies of Cimstar 3800 in F344/NTac rats and B6C3F1/N mice and toxicology and carcinogenesis studies of Cimstar 3800 in Wistar Han [Crl:WI(Han)] rats and B6C3F1/N mice (inhalation studies). NTP Technical Report Series. Accessed June 18, 2014. http://ntp.niehs.nih.gov/ntp/about-ntp/trpanel/2014/may/draft-tr586-508.pdf#search=cimstar%203800.
31. NTP (National Toxicology Program). (2014c). Toxicology studies of green tea extract in F344/NTac rats and B6C3F1/N mice and toxicology and carcinogenesis studies of green tea extract in Wistar Han[Crl:WI(Han)] rats and B6C3F1/N mice (gavage studies). NTP Technical Report Series. Accessed June 18, 2014. http://ntp.niehs.nih.gov/?objectid=BD499CD4-123F-7908-7B1F22BDE9A5D1D7.
32. NTP (National Toxicology Program). (2014d). Toxicology studies of pentabromodiphenyl oxide (technical) (DE 71)-M20287 (CASRN: 32534-81-9) in F344/N rats and B6C3F1/N mice and toxicology and carcinogenesis studies of pentabromodiphenyl oxide (technical) (DE 71)-M20287 in Wistar Han [Crl:WI(Han)] rats and B6C3F1/N mice (gavage studies). NTP Technical Report Series. Accessed June 18, 2014. http://ntp.niehs.nih.gov/?objectid=BD73BA18-123F-7908-7BD4AEF6AB4318BF.
33. Oreskovic S., Babic D., Kalafatic D., Barisic D., Beketic-Oreskovic L., (2004). A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Gynecol Oncol 93, 34-40.
34. Piegorsch W. W., Bailer A. J., (1997). Statistics for Environmental Biology and Toxicology,. Section 6.3.2. Chapman and Hall, London, UK.
35. Portier C. J., Bailer A. J., (1989). Testing for increased carcinogenicity using a survival-adjusted quantal response test. Fundam Appl Toxicol 12, 731-37.
36. Ryan A. J., Susil B., Jobling T. W., Oehler M. K., (2005). Endometrial cancer. Cell Tissue Res 322, 53-61.
37. Salvesen H. B., Iversen O. E., Akslen L. A., (1999). Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: A population-based endometrial carcinoma study. J Clin Oncol 17, 1382-90.
38. Samuelson E., Hedberg C., Nilsson S., Behboudi A., (2009). Molecular classification of spontaneous endometrial adenocarcinomas in BDII rats. Endocr Relat Cancer 16, 99-111.
39. Schauer U. M., Volkel W., Dekant W., (2006). Toxicokinetics of tetrabromobisphenol a in humans and rats after oral administration. Toxicol Sci 91, 49-58.
40. Vollmer G., (2003). Endometrial cancer: Experimental models useful for studies on molecular aspects of endometrial cancer and carcinogenesis. Endocr Relat Cancer 10, 23-42.
41. Wu R., Hendrix-Lucas N., Kuick R., Zhai Y., Schwartz D. R., Akyol A., Hanash S., Misek D. E., Katabuchi H., Williams B. O., Fearon E. R., Cho K. R., (2007). Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 11, 321-33.
42. Zannoni G. F., Vellone V. G., Arena V., Prisco M. G., Scambia G., Carbone A., Gallo D., (2010). Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study. Virchows Arch 457, 27-34.